Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Current Opinion in Chemical Biology

• Publication date

  2013-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.cbpa.2013.04.016PMID 23683349
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fragment based drug discovery: practical implementation based on ¹⁹F NMR spectroscopy.

  2012cited by this paper
• Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS Aβ Reduction.

  2012cited by this paper
• A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

  2012cited by this paper
• Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor.

  2012cited by this paper
• Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.

  2012cited by this paper
• Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.

  2012cited by this paper
• Acyl guanidine inhibitors of β-secretase (BACE-1): optimization of a micromolar hit to a nanomolar lead via iterative solid- and solution-phase library synthesis.

  2012cited by this paper
• Introduction to fragment-based drug discovery.

  2012cited by this paper
• New aminoimidazoles as β-secretase (BACE-1) inhibitors showing amyloid-β (Aβ) lowering in brain.

  2012cited by this paper
• Fragment-based approaches in drug discovery and chemical biology.

  2012cited by this paper
• Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation.

  2012cited by this paper
• Small-molecule BACE1 inhibitors: a patent literature review (2006 – 2011)

  2012cited by this paper
• Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease*

  2012cited by this paper
• Discovery and optimization of a novel spiropyrrolidine inhibitor of β-secretase (BACE1) through fragment-based drug design.

  2012cited by this paper
• Experiences in fragment-based drug discovery.

  2012cited by this paper
• Aminoimidazoles as BACE-1 inhibitors: the challenge to achieve in vivo brain efficacy.

  2012cited by this paper
• From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1).

  2011cited by this paper
• Triazole-linked reduced amide isosteres: an approach for the fragment-based drug discovery of anti-Alzheimer's BACE1 inhibitors.

  2011cited by this paper
• The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

  2011cited by this paper
• Fragment-based drug design - tools, practical approaches, and examples. Preface.

  2011cited by this paper
• Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor

  2011cited by this paper
• Fragment-based drug design : tools, practical approaches, and examples

  2011cited by this paper
• Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model.

  2010cited by this paper
• Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors.

  2010cited by this paper
• Fragment-based discovery and optimization of BACE1 inhibitors.

  2010cited by this paper
• Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation.

  2010cited by this paper
• Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes.

  2010cited by this paper
• Discovery and initial optimization of 5,5'-disubstituted aminohydantoins as potent beta-secretase (BACE1) inhibitors.

  2010cited by this paper
• Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors.

  2009cited by this paper
• Fragment-based discovery of nonpeptidic BACE-1 inhibitors using tethering.

  2009cited by this paper
• Progress toward the development of a viable BACE‐1 inhibitor

  2009cited by this paper
• Synthesis and SAR of hydroxyethylamine based phenylcarboxyamides as inhibitors of BACE.

  2009cited by this paper
• Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.

  2009cited by this paper
• Tyramine fragment binding to BACE-1.

  2008cited by this paper
• Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase.

  2007cited by this paper
• Application of fragment screening by X-ray crystallography to beta-secretase.

  2007cited by this paper
• Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency.

  2007cited by this paper
• Discovery of a novel warhead against beta-secretase through fragment-based lead generation.

  2007cited by this paper
• Ligand efficiency: a useful metric for lead selection.

  2004cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.

  2001cited by this paper
• Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein.

  2000cited by this paper
• Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor.

  2000cited by this paper
• Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases?

  1999cited by this paper
• Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity

  1999cited by this paper
• Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.

  1999cited by this paper
• Purification and cloning of amyloid precursor protein β-secretase from human brain

  1999cited by this paper
• Identification of a novel aspartic protease (Asp 2) as beta-secretase.

  1999cited by this paper
• Discovering High-Affinity Ligands for Proteins: SAR by NMR

  1996cited by this paper

• Identification of BACE-1 inhibitors through directed C(sp3)-H activation on 5-oxo-pyrrolidine-3-carboxylic acid derivatives.

  2024cites this paper
• Pharmacophore-based virtual screening of commercial databases against β-secretase 1 for drug development against Alzheimer’s disease

  2024cites this paper
• Synthesis, in vitro activity, and molecular docking of caffeic acid and resveratrol derivatives against Alzheimer’s disease-related enzymes

  2024cites this paper
• BACE-1 Inhibitors Targeting Alzheimer's Disease.

  2023cites this paper
• Potassium tert ‐Butoxide‐Mediated Synthesis of 2‐Aminoquinolines from Alkylnitriles and 2‐Aminobenzaldehyde Derivatives

  2022cites this paper
• Targeting caspase-2 interactions with tau in Alzheimer's disease and related dementias.

  2022cites this paper
• Synthesis and crystal structures of arylamidine Ru(III) compounds containing a tetradentate Schiff base ligand from a amine-amine coupling reaction

  2021cites this paper
• Sulfur-containing therapeutics in the treatment of Alzheimer’s disease

  2021cites this paper
• Application of Fragment-Based Drug Discovery to Versatile Targets

  2020cites this paper
• Insights into Structures and Dynamics of Flavivirus Proteases from NMR Studies

  2020cites this paper
• Blood-brain barrier–penetrating siRNA nanomedicine for Alzheimer’s disease therapy

  2020cites this paper
• Synthesis of Cyclic Amidines by Iridium-Catalyzed Deoxygenative Reduction of Lactams and Tandem Reaction with Sulfonyl Azides.

  2020cites this paper
• Synthesis of Amidines by Palladium-Mediated CO2 Extrusion Followed by Insertion of Carbodiimides: Translating Mechanistic Studies to Develop a One-Pot Method

  2019cites this paper
• A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment

  2019cites this paper
• Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety.

  2018cites this paper
• Stereodiversified Modular Synthesis of Non-planar Five-Membered Cyclic N -Hydroxylamidines: Reactivity Study and Application to the Synthesis of Cyclic Amidines

  2018cites this paper
• Fragment-based virtual screening approach and molecular dynamics simulation studies for identification of BACE1 inhibitor leads

  2018cites this paper
• Novel multi-target compounds in the quest for new chemotherapies against Alzheimer's disease: An experimental and theoretical study.

  2018cites this paper
• A Metal-Free Three-Component Reaction of trans-β-Nitrostyrene Derivatives, Dibromo Amides, and Amines Leading to Functionalized Amidines.

  2018cites this paper
• Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting.

  2017cites this paper
• 8.09 – Verubecestat

  2017cites this paper
• Hot-Spotting with Thermal Scanning: A Ligand- and Structure-Independent Assessment of Target Ligandability.

  2017cites this paper
• Computational approach for the assessment of inhibitory potency against beta-amyloid aggregation.

  2017cites this paper
• BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer’s Disease Pathology

  2017cites this paper
• Fragment Binding to β-Secretase 1 without Catalytic Aspartate Interactions Identified via Orthogonal Screening Approaches

  2017cites this paper
• Teaser Modern medicinal chemistry impacts drug discovery in many ways beyond just optimization of clinical candidates

  2017cites this paper
• Targeting β-Secretase (BACE) for the Treatment of Alzheimer’s Disease

  2017cites this paper
• Industrial medicinal chemistry insights: neuroscience hit generation at Janssen.

  2017cites this paper
• Synthesis of pyrimido[4,5-c]azepine- and pyrimido[4,5-c]oxepine-based γ-secretase modulators.

  2016cites this paper
• Targeting the BACE1 Active Site Flap Leads to a Potent Inhibitor That Elicits Robust Brain Aβ Reduction in Rodents.

  2016cites this paper
• Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs

  2016cites this paper
• Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.

  2016cites this paper
• Amyloid cascade in Alzheimer's disease: Recent advances in medicinal chemistry.

  2016cites this paper
• 2,2,2-Trifluoroethyl-thiadiazines: a patent evaluation of WO2016023927

  2016cites this paper
• Active Site Mapping of an Aspartic Protease by Multiple Fragment Crystal Structures: Versatile Warheads To Address a Catalytic Dyad.

  2016cites this paper
• Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates.

  2016cites this paper
• Discovery of S3-Truncated, C-6 Heteroaryl Substituted Aminothiazine β-Site APP Cleaving Enzyme-1 (BACE1) Inhibitors.

  2016cites this paper
• Opportunity Knocks: Organic Chemistry for Fragment-Based Drug Discovery (FBDD).

  2016cites this paper
• Discovery of furo[2,3-d][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors.

  2016cites this paper
• Fragment Screening in Complex Systems

  2016cites this paper
• Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting

  2016cites this paper
• Organische Chemie für die fragmentbasierte Wirkstoffentwicklung (FBDD)

  2016cites this paper
• Fragment‐Based Lead Generation

  2016cites this paper
• Selecting the Right Targets for Fragment‐Based Drug Discovery

  2016cites this paper
• Fragment-Linking Approach Using (19)F NMR Spectroscopy To Obtain Highly Potent and Selective Inhibitors of β-Secretase.

  2016cites this paper
• Expedient Synthesis of Furo[2,3-d][1,3]thiazinamines and Pyrano[2,3-d][1,3]thiazinamines from Enones and Thiourea.

  2016cites this paper
• From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer's Disease.

  2015cites this paper
• Preparation and biological evaluation of conformationally constrained BACE1 inhibitors.

  2015cites this paper
• Iminopyrimidinones: a novel pharmacophore for the development of orally active renin inhibitors.

  2015cites this paper
• Elucidating Mechanisms of Neuronal Dysfunction Caused by Familial Alzheimer's Disease Mutations in iPSC Derived Neurons

  2015cites this paper
• Structure‐based Drug Design Using NMR

  2015cites this paper
• Protein X‐Ray Crystallography in Structure‐Based Drug Design

  2015cites this paper
• Probucol mitigates streptozotocin-induced cognitive and biochemical changes in mice.

  2015cites this paper
• Palladium-catalyzed three-component reaction of N-tosyl hydrazones, isonitriles and amines leading to amidines.

  2015cites this paper
• Virtual fragment screening on GPCRs: a case study on dopamine D3 and histamine H4 receptors.

  2014cites this paper
• Detection of the Alzheimer's disease soluble amyloid precursor protein and modulation of its proteolytic processing

  2014cites this paper
• Data-mining for sulfur and fluorine: an evaluation of pharmaceuticals to reveal opportunities for drug design and discovery.

  2014cites this paper
• Application of Computational Methods for the Design of BACE-1 Inhibitors: Validation of in Silico Modelling

  2014cites this paper
• Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects

  2014cites this paper
• Computation Of Hydrogen Bond Basicity As A Descriptor In Bioisosterism: A Quantum Chemical Topology Perspective.

  2013cites this paper
• Multiple ligand docking by Glide: implications for virtual second-site screening

  2012cites this paper